Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$5.99 +4.2%	$4.03	$1.10 ▼ $6.35	$208.83M	0.43	859,387 shs	879,495 shs
MRMD MariMed	$0.18 +16.9%	$0.11	$0.07 ▼ $0.20	$60.13M	3.01	2.04 million shs	5.74 million shs
RAPT Rapt Therapeutics	$11.87 +4.3%	$10.42	$5.67 ▼ $26.56	$188.20M	-0.1	106,573 shs	34,459 shs
TIL Instil Bio	$29.22 +8.2%	$26.48	$10.80 ▼ $92.00	$182.27M	2.16	101,522 shs	107,381 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	0.00%	-3.36%	+70.62%	+193.37%	+418.02%
MRMD MariMed	0.00%	+33.91%	+57.95%	+110.10%	-16.98%
RAPT Rapt Therapeutics	0.00%	+4.60%	+8.48%	+43.98%	-30.78%
TIL Instil Bio	0.00%	+5.02%	+21.46%	-9.70%	+93.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMRX Immuneering	2.959 of 5 stars	3.3	2.0	0.0	1.9	5.0	0.6
MRMD MariMed	0.3967 of 5 stars	0.0	3.0	0.0	2.8	0.8	0.0
RAPT Rapt Therapeutics	4.2057 of 5 stars	4.3	2.0	4.2	1.6	1.7	0.6
TIL Instil Bio	3.5706 of 5 stars	3.5	4.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMRX Immuneering	2.60	Moderate Buy	$13.00	117.03% Upside
MRMD MariMed	4.00	Strong Buy	N/A	N/A
RAPT Rapt Therapeutics	2.50	Moderate Buy	$21.57	81.73% Upside
TIL Instil Bio	3.00	Buy	$119.00	307.26% Upside

Current Analyst Ratings Breakdown

Latest MRMD, TIL, IMRX, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/26/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
8/22/2025	RAPT Rapt Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/14/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/13/2025	MRMD MariMed	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMRX Immuneering	N/A	N/A	N/A	N/A	$1.33 per share	N/A
MRMD MariMed	$157.96M	0.44	$0.03 per share	7.14	$0.16 per share	1.13
RAPT Rapt Therapeutics	$1.53M	128.32	N/A	N/A	$11.51 per share	1.03
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMRX Immuneering	-$61.04M	-$1.89	N/A	N/A	N/A	N/A	-146.28%	-117.22%	11/12/2025 (Estimated)
MRMD MariMed	-$12.16M	-$0.03	N/A	∞	N/A	-10.14%	-10.52%	-3.10%	11/5/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	11/11/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$12.92	N/A	N/A	N/A	N/A	-54.32%	-33.65%	11/12/2025 (Estimated)

Latest MRMD, TIL, IMRX, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IMRX Immuneering	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMRX Immuneering	N/A	3.70	3.70
MRMD MariMed	1.25	1.12	0.36
RAPT Rapt Therapeutics	N/A	13.25	13.25
TIL Instil Bio	0.64	14.97	14.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMRX Immuneering	67.65%
MRMD MariMed	0.18%
RAPT Rapt Therapeutics	99.09%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
IMRX Immuneering	22.90%
MRMD MariMed	18.99%
RAPT Rapt Therapeutics	6.60%
TIL Instil Bio	46.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMRX Immuneering	60	36.32 million	28.00 million	Not Optionable
MRMD MariMed	260	390.43 million	316.29 million	Not Optionable
RAPT Rapt Therapeutics	80	16.54 million	15.45 million	Optionable
TIL Instil Bio	410	6.75 million	3.61 million	No Data

MRMD, TIL, IMRX, and RAPT Headlines

Recent News About These Companies

Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company

August 16, 2025 | finance.yahoo.com

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | finanznachrichten.de

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

Instil Bio Reports Promising Phase 2 Study Results

August 11, 2025 | theglobeandmail.com

Instil Bio stock rises after positive data for cancer therapy in China

July 31, 2025 | za.investing.com

Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test

July 31, 2025 | fiercebiotech.comF

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025 | globenewswire.com

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4, 2025 | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRMD, TIL, IMRX, and RAPT Company Descriptions

Immuneering NASDAQ:IMRX

$5.99 +0.24 (+4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$6.01 +0.02 (+0.40%)

As of 07:55 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

MariMed OTCMKTS:MRMD

$0.18 +0.03 (+16.88%)

As of 03:59 PM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Rapt Therapeutics NASDAQ:RAPT

$11.87 +0.49 (+4.31%)

Closing price 04:00 PM Eastern

Extended Trading

$11.96 +0.09 (+0.76%)

As of 05:19 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Instil Bio NASDAQ:TIL

$29.22 +2.22 (+8.22%)

Closing price 04:00 PM Eastern

Extended Trading

$28.73 -0.49 (-1.69%)

As of 07:31 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time